You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
|
|---|---|
| Published in |
Investigational New Drugs, April 2014
|
| DOI | 10.1007/s10637-014-0089-2 |
| Pubmed ID | |
| Authors |
Fatima Rangwala, Johanna C. Bendell, Mark F. Kozloff, Christy C. Arrowood, Andrew Dellinger, Jennifer Meadows, Sandra Tourt-Uhlig, Jennifer Murphy, Kellen L. Meadows, Aijing Starr, Samuel Broderick, John C. Brady, Stephanie M. Cushman, Michael A. Morse, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, James Wallace, Alexander N. Starodub, John H. Strickler, Herbert Pang, Andrew B. Nixon, Herbert I. Hurwitz |
| Abstract |
To define maximum tolerated dose (MTD), toxicities, and pharmacodynamics of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumor patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 16% |
| Student > Bachelor | 6 | 16% |
| Researcher | 6 | 16% |
| Other | 4 | 11% |
| Student > Master | 4 | 11% |
| Other | 7 | 19% |
| Unknown | 4 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 54% |
| Nursing and Health Professions | 6 | 16% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Arts and Humanities | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 4 | 11% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 March 2015.
All research outputs
#20,263,155
of 22,793,427 outputs
Outputs from Investigational New Drugs
#977
of 1,168 outputs
Outputs of similar age
#195,031
of 228,142 outputs
Outputs of similar age from Investigational New Drugs
#15
of 16 outputs
Altmetric has tracked 22,793,427 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,168 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,142 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.